AbbVie has reported full-year 2022 net revenues of $58.054bn, representing a 3.3% rise on a reported basis and 5.1% on an operational basis.

The company reported an increase of 1.6% on a reported basis in global net revenues to $15.121bn for the fourth quarter (Q4) of 2022.

For the full-year, worldwide net revenues from the Immunology portfolio stood at $28.924bn, increasing 14.4% on a reported basis.

Global net revenues of Humira for the full year stood at $21.237bn.

AbbVie also reported global Skyrizi and Rinvoq net revenues of $5.165bn and $2.522bn, respectively.

AbbVie chairman and CEO Richard Gonzalez said: “2022 was another highly productive year capping a decade of outstanding performance. Since our inception, we have built a diverse portfolio of growth products with significant leadership positions, developed a robust pipeline of innovative assets and created a culture of strong execution.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Looking forward, we have a solid foundation which will allow us to absorb the US Humira loss of exclusivity, return to strong top-line growth in 2025 and drive top-tier financial performance over the long term.”

The company’s full-year worldwide net revenues from the Hematologic Oncology portfolio stood at $6.577bn, a 9% decline on a reported basis.

Imbruvica and Venclexta net revenues worldwide were $4.568bn and $2.009bn, respectively.

The Neuroscience portfolio reported full-year global net revenues of $6.528bn, which represented a 10.1% rise on a reported basis.

Additionally, AbbVie reported fourth-quarter diluted EPS of $1.38 on a GAAP Basis, a 38.9% decline.

Last month, AbbVie signed a global partnership and option agreement with Immunome to discover new antibody-target pairs to treat cancer.